Related Experiment Video
Updated: Apr 14, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.2K
LDL-cholesterol lowering and renal outcomes
1Division of Cardiology, San Francisco General Hospital, Department of Medicine, University of California, San Francisco, California, USA.
Current Opinion in Lipidology
|April 19, 2015
Summary
Statins offer cardiovascular benefits for most patients with chronic kidney disease (CKD), with a small positive impact on kidney function. Guidelines recommend statins for older CKD patients and younger high-risk individuals.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Patients with chronic kidney disease (CKD) face elevated cardiovascular event risks.
- Statins are widely used to mitigate cardiovascular risk across diverse patient populations.
Purpose of the Study:
- To review evidence on statin efficacy in reducing cardiovascular risk among CKD patients.
- To assess the impact of statins on renal function in CKD.
- To summarize current lipid management guidelines for CKD patients.
Main Methods:
- Review of randomized controlled trials and meta-analyses on statin use in CKD.
- Analysis of guideline recommendations for lipid management in CKD.
Main Results:
- Statins demonstrated cardiovascular benefits in a broad range of CKD patients, though benefit decreased with CKD severity.
- No significant benefit was observed in patients undergoing dialysis.
- Statins showed a modest, favorable effect on preserving renal function over time.
- Recent guidelines advocate statin therapy for CKD patients aged 50+, younger high-risk individuals, and renal transplant recipients.
Conclusions:
- Statins are recommended for older patients with CKD.
- Younger CKD patients with high cardiovascular disease (CVD) risk should also receive statin therapy.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
01:17Factors Affecting Renal Clearance: Renal Impairment
560
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
560
01:26Atherosclerosis III: Management
603
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
332
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
332
01:26Coronary Artery Disease IV: Preventive Measures
867
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
867
01:06Renal Drug Clearance: Overview
1.0K
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
1.0K